Chinook Therapeutics

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science. The company focuses on developing precision medicines for kidney diseases. Its services offers utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints.

XPeng

Markets stayed solid to kick off the trading week. XPeng shares rose as the EV maker reported strong pre-sales volumes for its new SUV.

XPeng's New EV Is a Hit, but This Biotech Stock Is Leaving It in the Dust

Chinook Therapeutics (NASDAQ: KDNY ) stock is rocketing higher on Monday after the company announced it's being acquired by Novartis AG (NYSE: NVS ). Novartis AG is acquiring Chinook Therapeutics in a $3.2 billion deal.

Why Is Chinook Therapeutics (KDNY) Stock Up 58% Today?

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chinook Therapeutics, Inc. (NASDAQ: KDNY) to Novartis AG for $40.00 per share in cash is fair to Chinook shareholders. Additionally, Chinook shareholders will receive contingent value rights providing for payment of up to $4.00 per share upon the achievement of certain future regulatory milestones with respect to Chinook's lead product candidate, atrasentan. Halper Sadeh encourages Chi.

KDNY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chinook Therapeutics, Inc. Is Fair to Shareholders

Novartis

Chinook said it has entered an agreement to be acquired by Novartis for $40 per share in cash, with additional cash contingent on regulatory progress with astrasentan, its kidney disease drug candidate.

Chinook Therapeutics Stock Surges After Novartis Agrees $3.5 Billion Deal

Shares of Chinook Therapeutics KDNY, +0.17% rose 67% to $40.02 after it agreed to be bought by Novartis NVS, +0.28% for up to $3.5 billion. Holders of Chinook will receive $3.2 billion, or $40 per share, in cash upon closing, plus a contingent value right with a value of up to $0.3 billion, or $4 per share.

Chinook Therapeutics stock surges on deal to be bought for up to $3.5 billion by Novartis

Novartis agreed to acquire clinical-stage biopharmaceutical company Chinook Therapeutics for up to $3.5 billion, in a deal that will expand its portfolio of kidney disease treatments.

Novartis agrees to buy Chinook Therapeutics for up to $3.5 billion

Novartis said on Monday it agreed to acquire Seattle-based biotech firm Chinook Therapeutics for up to $3.5 billion to boost its late-stage drug development line-up with a new treatment for a rare severe kidney disease.

Novartis to buy Chinook for up to $3.5 bln in boost to late-stage pipeline

SEATTLE, June 12, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that it has entered into an agreement and plan of merger with Novartis AG pursuant to which Novartis will acquire Chinook for $40 per share in cash, or a total of $3.2 billion. This offer represents a premium of 83 percent to Chinook's 60-day volume-weighted average stock price and 67 percent to Chinook's closing price on June 9, 2023. In addition, Chinook shareholders will receive contingent value rights (CVRs) providing for payment of up to $4 per share upon the achievement of certain future regulatory milestones with respect to Chinook's lead product candidate, atrasentan. Total consideration including the contingent value right, if the milestones are achieved, would be approximately $3.5 billion. The transaction has been unanimously approved by the Boards of Directors of both companies.

Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG

NEW YORK , June 10, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Chinook Therapeutics, Inc. ("Chinook" or the "Company") (NASDAQ: KDNY). If you suffered losses exceeding $50,000 investing in Chinook stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

CHINOOK SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Chinook To Contact Him Directly To Discuss Their Options

NEW YORK , June 3, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Chinook Therapeutics, Inc. ("Chinook" or the "Company") (NASDAQ: KDNY). If you suffered losses exceeding $50,000 investing in Chinook stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

CHINOOK INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Chinook To Contact Him Directly To Discuss Their Options

NEW YORK , May 27, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Chinook Therapeutics, Inc. ("Chinook" or the "Company") (NASDAQ: KDNY). If you suffered losses exceeding $50,000 investing in Chinook stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

CHINOOK INVESTOR ALERT : Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Chinook To Contact Him Directly To Discuss Their Options

LOS ANGELES, CA / ACCESSWIRE / May 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Chinook Therapeutics, Inc. (“Chinook” or the “Company”) (NASDAQ: KDNY) on behalf of Chinook stockholders. Our investigation concerns whether Chinook has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. The investigation focuses on whether the Company issued fals.

CHINOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Chinook Therapeutics, Inc. on Behalf of Chinook Stockholders and Encourages Investors to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Chinook Therapeutics, Inc. (“Chinook” or the “Company”) (NASDAQ: KDNY) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Chinook investments or would like to inquire about potentially pursuing claims to recover your loss under the federal secur.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Chinook Therapeutics, Inc. (KDNY) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Chinook Therapeutics, Inc. (“Chinook” or the “Company”) (NASDAQ: KDNY) investors concerning the Company's possible violations of federal securities laws. On May 16, 2023, Muddy Waters Research published a report alleging that Chinook's lead product candidate, atrasentan, “has been shown to be harmful to patients' cardiovascular health,” and that “AbbVie and Chinook seem to have systemically ma.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Chinook Therapeutics, Inc. (KDNY) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $KDNY #KDNY--The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Chinook Therapeutics, Inc. (“Chinook” or the “Company”) (NASDAQ: KDNY) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On May 16, 2023, Muddy Waters Research published a report alleging that Chinook's lead product candidate, atrasentan, “has been shown to be harmful to patients' cardi.

The Law Offices of Frank R. Cruz Announces Investigation of Chinook Therapeutics, Inc. (KDNY) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Chinook Therapeutics, Inc. (NASDAQ: KDNY) resulting from allegations that Chinook may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Chinook securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arran.

KDNY INVESTOR NEWS: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Chinook Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – KDNY

SEATTLE, May 16, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced it has entered a collaboration agreement with Ionis Pharmaceuticals, Inc. for the discovery, development and commercialization of an antisense oligonucleotide (ASO) therapy for a rare, severe chronic kidney disease with significant unmet medical need. The companies will leverage Chinook's precision medicine approach and deep expertise in nephrology and Ionis' extensive expertise in RNA-targeted therapeutics.

Chinook Therapeutics Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney Disease

Chinook Therapeutics (KDNY) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $0.54 per share a year ago.

Chinook Therapeutics (KDNY) Reports Q1 Loss, Tops Revenue Estimates

SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today reported financial results for the first quarter ended March 31, 2023 and provided corporate updates.

Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updates

SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensation Committee of the Company's Board of Directors approved new employment inducement grants of stock options to purchase a total of 88,000 shares of common stock and restricted stock units for 44,600 shares with a grant date of April 28, 2023 (the “Inducement Grants”) for eleven new employees pursuant to the Company's 2022 Equity Inducement Plan.

Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming data presentations at the 60th ERA Congress from June 15 – 18, 2023, both virtual and live in Milan, Italy. The five accepted abstracts will be delivered as three focused orals (digital poster with 3-minute presentation), one free communication (10-minute live oral presentation) and one moderated oral presentation (6-slide presentation).

Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) Congress

SEATTLE , April 27, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in the following upcoming investor conferences:

Chinook Therapeutics to Present at Upcoming Investor Conferences

Chinook: CHK-336 Trial Pause Creates Buying Opportunity, All Eyes On IgAN Readout.

News for Chinook Therapeutics Stock (KDNY)